NCT04830449View on ClinicalTrials.gov

Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

October 29, 2020

Primary Completion Date

August 24, 2021

Study Completion Date

August 24, 2021

Conditions
Hypertension
Interventions
DRUG

HCP1904-2

Take it once daily for 8 weeks orally.

DRUG

RLD2001-2

Take it once daily for 8 weeks orally.

Trial Locations (1)

03722

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT04830449 - Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients | Biotech Hunter | Biotech Hunter